Followers | 1078 |
Posts | 80316 |
Boards Moderated | 8 |
Alias Born | 03/10/2009 |
Tuesday, August 28, 2018 9:25:31 PM
On August 28, 2018, Assertio Therapeutics, Inc., a Delaware corporation (the “ Company ”), and each of Purdue Pharma L.P., a Delaware limited partnership, The P.F. Laboratories, Inc. a New Jersey corporation, and Purdue Pharmaceuticals L.P., a Delaware limited partnership (collectively, “ Purdue ”), entered into a Settlement Agreement with respect to the Company’s lawsuit against Purdue Pharma L.P for patent infringement filed in January 2013 in the U.S. District Court for the District of New Jersey. The lawsuit arose from Purdue’s commercialization of reformulated OxyContin® (oxycodone hydrochloride controlled-release) in the U.S. and alleged infringement of U.S. Patent Nos. 6,340,475 and 6,635,280, which expired in September 2016.
Pursuant to the Settlement Agreement: (i) Purdue will pay the Company $30 million on August 28, 2018 and will pay the Company an additional $32 million on February 1, 2019; (ii) each party covenanted not to the sue the other with regard to any alleged infringement of such party’s patents or patent rights as a result of the commercialization of the other party’s current product portfolio; (iii) each party covenanted not to challenge the other party’s patents or patent rights covering such other party’s current product portfolio; and (iv) each party agreed to a mutual release of claims relating to any claim or potential claim relating to the other party’s current product portfolio.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
ASSERTIO THERAPEUTICS, INC.
Date: August 28, 2018
By:
/s/ Amar Murugan
Amar Murugan
Senior Vice President and General Counsel
STOP & VISIT MY BOARD AT: HOTTEST PENNY STOCK PICKS
http://investorshub.advfn.com/boards/board.aspx?board_id=19627
My posts are NOT a buy/sell recommendation, Do your Own DD, before you buy any stock - I reserve the right to buy/sell any stock
Recent ASRT News
- Assertio Holdings, Inc. to Report First Quarter 2024 Financial Results on May 6, 2024 • GlobeNewswire Inc. • 04/25/2024 12:00:05 PM
- Sig Kirk Joins Assertio Board of Directors • GlobeNewswire Inc. • 04/03/2024 12:00:00 PM
- Assertio to Present at LD Micro Invitational Conference in New York City • GlobeNewswire Inc. • 04/01/2024 01:00:18 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 03/11/2024 09:32:51 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/11/2024 09:09:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/11/2024 09:07:33 PM
- Assertio Reports Fourth Quarter and Full Year 2023 Financial Results • GlobeNewswire Inc. • 03/11/2024 08:01:00 PM
- U.S. Index Futures Dip Ahead of Inflation Data and Oracle’s Earnings; Oil Prices Edge Higher • IH Market News • 03/11/2024 10:39:47 AM
- The Gross Law Firm Notifies Assertio Holdings, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - ASRT • PR Newswire (US) • 03/05/2024 10:45:00 AM
- Assertio Holdings, Inc. to Release Fourth Quarter and Full Year 2023 Financial Results on March 11, 2024 • GlobeNewswire Inc. • 02/29/2024 09:05:00 PM
- Shareholders that lost money on Assertio Holdings, Inc.(ASRT) Urged to Join Class Action - Contact The Gross Law Firm to Learn More • PR Newswire (US) • 02/26/2024 10:45:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/23/2024 10:32:16 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/23/2024 10:30:20 PM
- Class Action Filed Against Assertio Holdings, Inc. (ASRT) - March 5, 2024 Deadline to Join - Contact The Gross Law Firm • PR Newswire (US) • 02/22/2024 10:45:00 AM
- Class Action Filed Against Assertio Holdings, Inc. (ASRT) Seeking Recovery for Investors - Contact The Gross Law Firm • PR Newswire (US) • 02/15/2024 10:05:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/14/2024 12:02:16 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/14/2024 12:01:38 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/14/2024 12:00:52 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 11:02:27 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 11:01:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 11:00:30 PM
- The Gross Law Firm Reminds Assertio Holdings, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 5, 2024 - ASRT • PR Newswire (US) • 02/09/2024 10:45:00 AM
- The Gross Law Firm Notifies Shareholders of Assertio Holdings, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of March 5, 2024 - (NASDAQ: ASRT) • PR Newswire (US) • 02/02/2024 10:45:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/26/2024 10:00:58 PM
- The Gross Law Firm Notifies Shareholders of Assertio Holdings, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of March 5, 2024 - (NASDAQ: ASRT) • PR Newswire (US) • 01/26/2024 10:45:00 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM